Skip to main content

Table 2 Primary outcome across all study groups

From: Infrared laser moxibustion for cancer-related fatigue in breast cancer survivors: a randomized controlled trial

Variable

Mean change in BFI score from baseline (95% CI)

 

ILM vs. SILM groups

ILM vs. WLC groups

ILM (n = 56)

SILM (n = 56)

WLC (n = 28)

 

Difference (95% CI)

aP value

Difference (95%CI)

aP value

week 3

-1.06 (-1.47,-0.66)

-0.70 (-0.96,-0.43)

-0.20 (-0.50,0.10)

 

-0.35 (-0.78,0.09)

0.1189

-0.80 (-1.32,-0.28)

0.0027

week 6

-1.39 (-1.87,-0.92)

-1.00 (-1.39,-0.62)

-0.39 (-0.84,0.06)

 

-0.36 (-0.92,0.20)

0.2060

-0.91 (-1.58,-0.25)

0.0072

week 12

-1.87 (-2.29,-1.44)

-1.27 (-1.66,-0.87)

-0.37 (-0.87,0.12)

 

-0.57 (-1.12,-0.03)

0.0392

-1.41 (-2.06,-0.76)

< 0.0001

week 18

-2.00 (-2.44,-1.57)

-1.24 (-1.70,-0.78)

-0.81 (-1.30,-0.31)

 

-0.74 (-1.32,-0.15)

0.0143

-1.11 (-1.81,-0.41)

0.0020

  1. Abbreviations: ILM: Infrared Laser Moxibustion; SILM: Sham Infrared Laser Moxibustion; WLC: Waitlist Control; BFI: Brief Fatigue Inventory
  2. aP values were calculated using a mixed-effects model